JP2021137024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021137024A5 JP2021137024A5 JP2021095192A JP2021095192A JP2021137024A5 JP 2021137024 A5 JP2021137024 A5 JP 2021137024A5 JP 2021095192 A JP2021095192 A JP 2021095192A JP 2021095192 A JP2021095192 A JP 2021095192A JP 2021137024 A5 JP2021137024 A5 JP 2021137024A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- antibody
- engineered
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023119583A JP7717762B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2023119584A JP7719128B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2025124172A JP2025169264A (ja) | 2015-02-06 | 2025-07-24 | 治療免疫細胞の有効性を改良するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112765P | 2015-02-06 | 2015-02-06 | |
| US62/112,765 | 2015-02-06 | ||
| US201562130970P | 2015-03-10 | 2015-03-10 | |
| US62/130,970 | 2015-03-10 | ||
| JP2017541243A JP6895380B2 (ja) | 2015-02-06 | 2016-02-05 | 治療免疫細胞の有効性を改良するための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541243A Division JP6895380B2 (ja) | 2015-02-06 | 2016-02-05 | 治療免疫細胞の有効性を改良するための方法 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023119584A Division JP7719128B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2023119583A Division JP7717762B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021137024A JP2021137024A (ja) | 2021-09-16 |
| JP2021137024A5 true JP2021137024A5 (enExample) | 2022-06-02 |
| JP7320560B2 JP7320560B2 (ja) | 2023-08-03 |
Family
ID=56564429
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541243A Active JP6895380B2 (ja) | 2015-02-06 | 2016-02-05 | 治療免疫細胞の有効性を改良するための方法 |
| JP2021095192A Active JP7320560B2 (ja) | 2015-02-06 | 2021-06-07 | 治療免疫細胞の有効性を改良するための方法 |
| JP2023119583A Active JP7717762B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2023119584A Active JP7719128B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2025124172A Pending JP2025169264A (ja) | 2015-02-06 | 2025-07-24 | 治療免疫細胞の有効性を改良するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541243A Active JP6895380B2 (ja) | 2015-02-06 | 2016-02-05 | 治療免疫細胞の有効性を改良するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023119583A Active JP7717762B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2023119584A Active JP7719128B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2025124172A Pending JP2025169264A (ja) | 2015-02-06 | 2025-07-24 | 治療免疫細胞の有効性を改良するための方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10765699B2 (enExample) |
| EP (2) | EP4134430A1 (enExample) |
| JP (5) | JP6895380B2 (enExample) |
| KR (2) | KR20250022235A (enExample) |
| CN (4) | CN107709548B (enExample) |
| AU (3) | AU2016216149B2 (enExample) |
| CA (1) | CA2975851A1 (enExample) |
| DK (1) | DK3253865T3 (enExample) |
| ES (1) | ES2926384T3 (enExample) |
| HR (1) | HRP20220890T1 (enExample) |
| HU (1) | HUE059662T2 (enExample) |
| LT (1) | LT3253865T (enExample) |
| PL (1) | PL3253865T3 (enExample) |
| PT (1) | PT3253865T (enExample) |
| RS (1) | RS63574B1 (enExample) |
| SG (2) | SG11201706236SA (enExample) |
| SI (1) | SI3253865T1 (enExample) |
| SM (1) | SMT202200353T1 (enExample) |
| WO (1) | WO2016126213A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| SG11201706236SA (en) * | 2015-02-06 | 2017-08-30 | Nat Univ Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| KR102632082B1 (ko) | 2015-02-27 | 2024-02-02 | 아이셀 진 테라퓨틱스 엘엘씨 | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 |
| KR20230091191A (ko) | 2016-05-27 | 2023-06-22 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| EP3494132A4 (en) * | 2016-08-03 | 2020-03-18 | Washington University | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| CN109689693B (zh) * | 2016-11-03 | 2022-06-28 | 深圳华大生命科学研究院 | 提高基因编辑效率的方法和系统 |
| AU2017363278B2 (en) | 2016-11-22 | 2022-10-27 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| WO2018156434A1 (en) | 2017-02-22 | 2018-08-30 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tim3-binding chimeric antigen receptors |
| WO2018169922A2 (en) * | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| SG11201908337VA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| AU2018313939A1 (en) * | 2017-08-10 | 2020-02-06 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
| CA3079076A1 (en) * | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
| CA3078963A1 (en) | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies |
| WO2019129851A1 (en) * | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
| MX2020007880A (es) * | 2018-01-25 | 2021-05-14 | Cullinan Mica Corp | Anticuerpos de mica/b y metodos de uso. |
| CN108314739B (zh) * | 2018-02-05 | 2020-07-14 | 深圳市默赛尔生物医学科技发展有限公司 | 多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用 |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| JP7266611B2 (ja) * | 2018-02-26 | 2023-04-28 | アブリンクス・エヌ・フェー | ペプチドリンカーをコードする改良されたヌクレオチド配列 |
| SG11202008976YA (en) * | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| AU2019275076B2 (en) * | 2018-05-23 | 2024-12-19 | National University Of Singapore | Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies |
| JP2021525530A (ja) | 2018-06-01 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
| KR102839381B1 (ko) | 2018-08-29 | 2025-07-28 | 내셔널 유니버시티 오브 싱가포르 | 유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법 |
| CN109207430A (zh) * | 2018-09-25 | 2019-01-15 | 华东师范大学 | 一种嵌合抗原受体nk细胞及其制备方法和应用 |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| KR20200049594A (ko) * | 2018-10-24 | 2020-05-08 | 주식회사 툴젠 | 조작된 면역 세포 |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| MA53877A (fr) | 2018-11-14 | 2022-01-19 | MediSix Therapeutics Pte Ltd | Vecteurs à deux gènes pour la génération de cellules car-t et utilisations associées |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| GB201914611D0 (en) * | 2019-10-09 | 2019-11-20 | Autolus Ltd | Engineered immune cell |
| US20240082399A1 (en) * | 2019-10-11 | 2024-03-14 | The Board Of Trustees Of The Leland Stanford Junior University | Recombinant polypeptides for regulatable cellular localization |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN113005088B (zh) * | 2019-12-19 | 2024-06-04 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
| CN113088495B (zh) * | 2020-01-09 | 2024-08-16 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
| KR20220147109A (ko) * | 2020-02-27 | 2022-11-02 | 노파르티스 아게 | 키메라 항원 수용체 발현 세포의 제조 방법 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| EP4112721A4 (en) * | 2020-06-11 | 2024-02-28 | Bioheng Therapeutics Limited | GENETICALLY ENGINEERED IMMUNE CELL EXPRESSING NK-INHIBITING MOLECULES AND THEIR USE |
| CA3186887A1 (en) | 2020-06-22 | 2021-12-30 | Ramot At Tel-Aviv University Ltd. | Multi subunit protein modules, cells expressing same and uses thereof |
| CN112195155A (zh) * | 2020-08-11 | 2021-01-08 | 广东万海细胞生物科技有限公司 | 一种通用car-t细胞及其制备方法 |
| CN120025983A (zh) * | 2020-11-03 | 2025-05-23 | 南京北恒生物科技有限公司 | 靶向cd7的嵌合抗原受体及其用途 |
| US20230051406A1 (en) | 2020-11-13 | 2023-02-16 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| EP4259782A1 (en) * | 2020-12-14 | 2023-10-18 | Allogene Therapeutics, Inc. | Methods and reagents for characterizing car t cells for therapies |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN113234682B (zh) * | 2021-01-12 | 2023-02-21 | 上海雅科生物科技有限公司 | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 |
| WO2022166365A1 (zh) * | 2021-02-03 | 2022-08-11 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
| EP4308133A4 (en) | 2021-03-17 | 2025-01-22 | Myeloid Therapeutics, Inc. | MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| IL308445A (en) | 2021-05-11 | 2024-01-01 | Myeloid Therapeutics Inc | Methods and compositions for genomic integration |
| CN113416701B (zh) * | 2021-07-28 | 2023-05-09 | 新疆西部赛澳生物科技有限责任公司 | 一种nk细胞培养基及培养方法 |
| WO2023006120A1 (zh) * | 2021-07-30 | 2023-02-02 | 羿尊生物医药（浙江）有限公司 | 通用型t细胞及其应用 |
| EP4649093A2 (en) | 2023-01-12 | 2025-11-19 | National University of Singapore | Blockade of cd8 expression and chimeric antigen receptors for immunotherapy of t-cell and nk-cell malignancies |
| WO2024154122A1 (en) | 2023-01-18 | 2024-07-25 | Gilboa Therapeutics LTD | Immune cells expressing a complement receptor and uses thereof |
| WO2024236557A1 (en) | 2023-05-12 | 2024-11-21 | Gilboa Therapeutics LTD | Compositions comprising an fc domain for the treatment of medical conditions |
| CN116731205B (zh) * | 2023-05-19 | 2024-02-27 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 一种表达TGFβRII和TIM3胞外区的免疫增强型融合蛋白及其应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| JP2001516766A (ja) | 1997-09-19 | 2001-10-02 | デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド | 免疫反応の細胞内発現抗体仲介制御 |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| AU2002211658A1 (en) | 2000-10-13 | 2002-04-22 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| WO2003051926A2 (en) | 2001-12-14 | 2003-06-26 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Anti-cd7 immunotoxin as fusion protein |
| KR20060079180A (ko) | 2003-07-02 | 2006-07-05 | 노보 노르디스크 에이/에스 | Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법 |
| US20090191213A9 (en) | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| AU2004309373A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
| WO2006003179A2 (en) | 2004-07-01 | 2006-01-12 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
| AU2005299353A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Llc | Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections |
| US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| JP4860703B2 (ja) | 2005-10-06 | 2012-01-25 | ゼンコー・インコーポレイテッド | 最適化された抗ｃｄ３０抗体 |
| WO2007126782A2 (en) * | 2006-03-28 | 2007-11-08 | Hampton University | Hadron treatment planning with adequate biological weighting |
| AU2008221118B2 (en) | 2007-03-01 | 2013-10-03 | Les Laboratoires Servier | Recombinant anti-epidermal growth factor receptor antibody compositions |
| PT2185574E (pt) | 2007-09-07 | 2013-08-26 | Agensys Inc | Anticorpos e moléculas relacionadas que se ligam a proteínas 24p4c12 |
| JP5774312B2 (ja) | 2008-01-24 | 2015-09-09 | ノボ・ノルデイスク・エー／エス | ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体 |
| JP2013508287A (ja) | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG11201404285VA (en) | 2012-02-22 | 2014-10-30 | Univ Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| RS59199B1 (sr) | 2012-05-25 | 2019-10-31 | Univ California | Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta |
| LT2872171T (lt) * | 2012-07-13 | 2021-04-26 | The Trustees Of The University Of Pennsylvania | Car priešnavikinio aktyvumo toksiškumo reguliavimas |
| EP3763810A3 (en) * | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| KR101521224B1 (ko) | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | T 세포 특이적인 인간화 단일조각항체 전달체 |
| JP2016503655A (ja) * | 2012-12-27 | 2016-02-08 | アデュロ バイオテック，インコーポレイテッド | リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用 |
| EP2953475B1 (en) | 2013-02-06 | 2019-07-03 | Celgene Corporation | Modified t lymphocytes having improved specificity |
| MX378463B (es) | 2013-02-26 | 2025-03-10 | Memorial Sloan Kettering Cancer Center | Composiciones y usos de las mismas para inmunoterapia. |
| EP2968520B1 (en) | 2013-03-14 | 2021-05-12 | MacroGenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
| AU2014273490B2 (en) | 2013-05-29 | 2019-05-09 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system |
| MX373687B (es) | 2013-11-21 | 2020-07-07 | Ucl Business Ltd | Célula natural (nk) |
| PT3105317T (pt) | 2014-02-14 | 2019-02-27 | Cellectis | Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas |
| GB201405845D0 (en) * | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| WO2016011210A2 (en) | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| CN107109368A (zh) | 2014-10-07 | 2017-08-29 | 塞勒克提斯公司 | 用于调节car诱导的免疫细胞活性的方法 |
| CN107206024B (zh) | 2014-10-31 | 2021-12-03 | 宾夕法尼亚大学董事会 | 改变cart细胞中的基因表达及其用途 |
| CA3224507A1 (en) | 2014-12-24 | 2016-06-30 | Autolus Limited | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
| US11161907B2 (en) * | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| SG11201706236SA (en) * | 2015-02-06 | 2017-08-30 | Nat Univ Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| KR102632082B1 (ko) | 2015-02-27 | 2024-02-02 | 아이셀 진 테라퓨틱스 엘엘씨 | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 |
| KR102133857B1 (ko) * | 2015-03-02 | 2020-07-20 | 이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드 | Ｐｄ－ｌ１에 의해 유도된 면역관용의 감소 |
| EP3310915A4 (en) | 2015-06-19 | 2019-04-10 | Massachusetts Institute of Technology | TUMOR IMMUNOTHERAPY |
| WO2017222593A1 (en) | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| IL257105B (en) | 2015-07-31 | 2022-09-01 | Univ Minnesota | Modified cells and methods of therapy |
| SG10201912792YA (en) | 2015-10-06 | 2020-02-27 | Univ Minnesota | Therapeutic compounds and methods |
| WO2017112877A1 (en) | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| WO2017213979A1 (en) | 2016-06-06 | 2017-12-14 | St. Jude Children's Research Hospital | Anti-cd7 chimeric antigen receptor and method of use thereof |
| CA2937157A1 (en) | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
| EP3494132A4 (en) | 2016-08-03 | 2020-03-18 | Washington University | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| AU2017363278B2 (en) | 2016-11-22 | 2022-10-27 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| GB201622044D0 (en) | 2016-12-22 | 2017-02-08 | Ucl Business Plc | T cell-targeted T cells |
| JP7717439B2 (ja) | 2017-01-10 | 2025-08-04 | ザ ジェネラル ホスピタル コーポレイション | 修飾されたｔ細胞及びその使用方法 |
| AU2018313939A1 (en) | 2017-08-10 | 2020-02-06 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
| MA53877A (fr) | 2018-11-14 | 2022-01-19 | MediSix Therapeutics Pte Ltd | Vecteurs à deux gènes pour la génération de cellules car-t et utilisations associées |
-
2016
- 2016-02-05 SG SG11201706236SA patent/SG11201706236SA/en unknown
- 2016-02-05 HR HRP20220890TT patent/HRP20220890T1/hr unknown
- 2016-02-05 SM SM20220353T patent/SMT202200353T1/it unknown
- 2016-02-05 PL PL16746922.0T patent/PL3253865T3/pl unknown
- 2016-02-05 KR KR1020257003185A patent/KR20250022235A/ko active Pending
- 2016-02-05 RS RS20220680A patent/RS63574B1/sr unknown
- 2016-02-05 CN CN201680018962.7A patent/CN107709548B/zh active Active
- 2016-02-05 CA CA2975851A patent/CA2975851A1/en active Pending
- 2016-02-05 CN CN202210667502.4A patent/CN115029362A/zh active Pending
- 2016-02-05 EP EP22180254.9A patent/EP4134430A1/en active Pending
- 2016-02-05 HU HUE16746922A patent/HUE059662T2/hu unknown
- 2016-02-05 EP EP16746922.0A patent/EP3253865B1/en active Active
- 2016-02-05 CN CN202210661143.1A patent/CN114891816B/zh active Active
- 2016-02-05 SG SG10201913124RA patent/SG10201913124RA/en unknown
- 2016-02-05 ES ES16746922T patent/ES2926384T3/es active Active
- 2016-02-05 US US15/548,577 patent/US10765699B2/en active Active
- 2016-02-05 AU AU2016216149A patent/AU2016216149B2/en active Active
- 2016-02-05 SI SI201631593T patent/SI3253865T1/sl unknown
- 2016-02-05 KR KR1020177024662A patent/KR102763121B1/ko active Active
- 2016-02-05 PT PT167469220T patent/PT3253865T/pt unknown
- 2016-02-05 JP JP2017541243A patent/JP6895380B2/ja active Active
- 2016-02-05 CN CN202111064400.5A patent/CN113713091A/zh active Pending
- 2016-02-05 WO PCT/SG2016/050063 patent/WO2016126213A1/en not_active Ceased
- 2016-02-05 DK DK16746922.0T patent/DK3253865T3/da active
- 2016-02-05 LT LTEPPCT/SG2016/050063T patent/LT3253865T/lt unknown
-
2020
- 2020-07-30 US US16/943,400 patent/US12404491B2/en active Active
-
2021
- 2021-06-07 JP JP2021095192A patent/JP7320560B2/ja active Active
-
2022
- 2022-06-29 AU AU2022204601A patent/AU2022204601B2/en active Active
- 2022-07-12 US US17/862,797 patent/US12404492B2/en active Active
- 2022-07-12 US US17/862,721 patent/US11679132B2/en active Active
-
2023
- 2023-07-24 JP JP2023119583A patent/JP7717762B2/ja active Active
- 2023-07-24 JP JP2023119584A patent/JP7719128B2/ja active Active
-
2025
- 2025-07-03 AU AU2025205077A patent/AU2025205077A1/en active Pending
- 2025-07-24 JP JP2025124172A patent/JP2025169264A/ja active Pending
- 2025-07-30 US US19/285,735 patent/US20250354119A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021137024A5 (enExample) | ||
| JP7719128B2 (ja) | 治療免疫細胞の有効性を改良するための方法 | |
| JP2023059873A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| Geldres et al. | Chimeric antigen receptor-redirected T cells return to the bench | |
| IL264104B1 (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| JP2019509764A (ja) | 初代細胞のためのトランスポゾンに基づく転移システム | |
| CN110616191B (zh) | 共刺激配体联合的car t疗法 | |
| JPWO2021173995A5 (enExample) | ||
| JP2023541132A (ja) | 免疫細胞におけるアダプターの誘導性発現のための系 | |
| JPWO2021205172A5 (enExample) | ||
| JP2025524457A (ja) | 哺乳動物におけるキメラ抗原受容体介在性の免疫応答を刺激するための方法において使用するためのｃｄ１２３に対する標的化モジュール | |
| WO2025140540A1 (zh) | 特异性靶向肿瘤的转基因重组免疫细胞及其应用 | |
| KR20250111218A (ko) | 혈액학적 암의 치료에 사용하기 위한 키트 | |
| HK40086170A (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| Debets et al. | TCR-Engineered T cells | |
| NZ734107B2 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| JPWO2022243565A5 (enExample) |